Trial Information: This is a Phase I study of AT7519M, an enzyme inhibitor which may impede cancerous cell growth. It will be given to 30 patients with incurable cancers, including solid tumours and advanced, refractory non-Hodgkin's lymphoma, including follicular lymphoma. Patients will receive varying dosages.
Background: This is a Phase I study, meaning the researchers are interested in assessing disease toxicity and defining an ideal dosage before proceeding to a Phase II study focusing directly on response rates.
AT7519M is a Cyclin-dependent kinase inhibitor (CKI). In a previous Phase I study, one lung cancer patient responded to therapy.
Canadian Locations: Hamilton, ON (Juravinski Cancer Centre); Toronto, ON (Princess Margaret Hospital).
More Information: See ClinicalTrials.gov (as of November 2010).
No comments:
Post a Comment